Latest News

Date Title Topic
20 Oct 2016 FDA Approves Atezolizumab for Metastatic NSCLC Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
19 Oct 2016 EMA Adopts a New Indication for Nivolumab Haematologic malignancies - Cancer Immunology and Immunotherapy
Video Highlights
18 Oct 2016 Withdrawal of the Marketing Authorisation Application for Cediranib Gynaecologic malignancies - Anticancer agents & Biologic therapy
17 Oct 2016 EMA Recommends Granting a Conditional Marketing Authorisation for Venetoclax Haematologic malignancies - Anticancer agents & Biologic therapy
Webcasts
11 Oct 2016 ESMO 2016 Press Release: Best of ESMO 2016 Congress
10 Oct 2016 ESMO 2016 Press Release: Longer Disease-free Survival in Phase III Trial of Sunitinib as Adjuvant Treatment for Kidney Cancer Genitourinary cancers
10 Oct 2016 ESMO 2016 Press Release: Single-Arm Trials Improve Early Access to Rare Cancer Drugs Translational research
10 Oct 2016 ESMO 2016 Press Release: Financial Difficulties Linked to Worse Outcomes From Cancer Treatment Bioethics, legal and economic issues
10 Oct 2016 ESMO 2016 Press Release: First Feasibility Study of the ESMO-MCBS Scale in Rare Tumour Entities Bioethics, legal and economic issues
10 Oct 2016 ESMO 2016 Press Release: Cabozantinib Improves Progression-free Survival in Metastatic Renal Cell Carcinoma Genitourinary cancers
10 Oct 2016 ESMO 2016 Press Release: MEK Inhibition in KRAS-mutant NSCLC Did Not Improve Survival Lung and other thoracic tumours
10 Oct 2016 ESMO 2016 Press Release: Custirsen Shows no Survival Benefits in Metastatic Prostate Cancer Genitourinary cancers
10 Oct 2016 ESMO 2016 Press Release: Significant Survival Gains from Neoadjuvant Chemotherapy for High-risk Soft Tissue Sarcoma Sarcomas